Articles On Biotron (ASX:BIT)

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Wall Street closed for Thanksgiving No major leads from global markets overnight, as Wall Street was closed for Thanksgiving. Elsewhere, new data showed COVID infections in Europe continue to surge higher. With winter approaching, the conti...

BIT225 administered orally significantly reduced viral load in the lungs and blood of animals challenged with SARS-CoV-2. BIT225 protected against severe disease, indicated by the significant prevention of body weight loss in animals trea...

The ASX closed just 0.11% higher today but there were no shortage of small cap winners, led by Antiviral biotechnology stock Biotron (ASX:BIT). It announced that its lead drug candidate — BIT225 — had been shown to be effective against COVI...

Antiviral biotechnology stock Biotron (ASX:BIT) turned heads on the ASX this morning, after announcing that its lead drug candidate — BIT225 — had been shown to be effective against COVID-19 in animals. After tracking from ~8c to below 5c t...

Biotron’s (BIT) lead drug, BIT225, has been effective against COVID-19 in animals The drug was given orally and significantly reduced viral load in the lungs and blood Additionally, the company also tested BIT225 in an in-vitro study in c...

The Biotron Limited (ASX: BIT) share price is rocketing upwards today after the company announced its lead clinical asset successfully treated COVID-19 symptoms in mice as part of a study. In the study, the drug, BIT225, was found to reduc...

Biotron (ASX:BIT) has announced that its lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations.

Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

In the spirit of the recently-concluded Olympics and ongoing Paralympics, congratulations to the backers of the radiopharmaceuticals group for a record-breaking performance after listing this week. In raising $92 million, Clarity (ASX:CU6)...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

It’s easy to just think of Pfizer and AstraZeneca as the only two companies fighting COVID-19 in Australia. But Biotron ... Read More The post AstraZeneca’s COVID-19 fight hits the skids; ASX small cap Biotron says ‘We’re on track’ appeared...

ASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndrome (ARDS). ARDS is a disease that hinders the lungs’ ability to operate and is a major culprit of COVID-19 deaths. Essentially it causes lun...

Summary ASX 200 listed retail company Unibail-Rodamco-Westfield disclosed a €9.0 billion RESET plan for strengthening its balance sheet and improving financial flexibility. Financial service provider FlexiGroup had completed Retail Enti...

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021... The...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to snap its losing streak with a solid gain. At the time of writing the benchmark index is up 0.4% to 5,949.2 points. Four shares that are climbing more than most today a...

The chase for effective COVID-19 treatments is well and truly on after biotech company Biotron (ASX: BIT) confirmed it intends to harness its proprietary compounds to develop a treatment for SARS-CoV-2, the coronavirus that causes the COVID...

Pharmaxis (ASX:PXS) and Biotron (ASX:BIT) have gone in polar opposite directions in 2020 and today the gap widened further. Biotron has now nearly doubled in 2020 while Pharmaxis has nearly halved. Pharmaxis ended 2019 with a big blow which...

The Biotron Limited (ASX: BIT) share price has rocketed higher on Monday after the release of an update. In early trade the clinical stage biotechnology company’s shares were up as much as 47% to 14 cents. They have since given back much o...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

The Biotron Limited (ASX: BIT) share price soared by 30% today, after the biotechnology company released new data regarding the effectiveness of its lead antiviral drug BIT225, used for fighting HIV-1 infections. The Biotron share price is...

A quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 576 declined and 819 were u...

Biotron’s (ASX: BIT) lead candidate HIV-1 drug BIT225 has been shown to boost the body’s immune response to HIV by inhibiting viral protein Vpu, while also having an anti-viral effect. The company is presenting new data on BIT225’s positive...

Biotron (ASX:BIT) has announced it will present the latest data on BIT225 HIV-1 at the 23rd International AIDS Conference (AIDS 2020: Virtual) in July.

Typically patients with HIV need to stay on treatment for life but that may no longer be the case if Biotron’s (ASX:BIT) anti-HIV therapy stacks up. The biotech has found that its anti-HIV therapy can restore immune functions in HIV patient...

The Biotron Limited (ASX: BIT) share price is soaring higher this morning after the small-cap ASX healthcare share released more data in relation to the effectiveness of its antiviral drug, BIT225. After rocketing as much as 21.7% higher i...

The S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is tumbling lower on Thursday. In morning trade the benchmark index is down 2.4% to 5,588.2 points. Four shares that have not let that hold them back are listed...

Jatenergy (ASX:JAT) shares are surging after the company said it booked record sales and revenue in February, as Chinese buyers sucked up its milk products. Revenue was $8.3m for the month. The board has lifted full year guidance from $36m...

Clinical stage company Biotron (ASX: BIT) is preparing to present results from its ongoing Phase 2 trial into its lead BIT225 drug at the annual Conference on Retroviral and Opportunistic Infections (CROI) this week with new data showing th...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

There are dozens of vaccines, antiretrovirals and new supportive therapies being feverishly tested against COVID-19, and researchers say new technologies are enabling them to move faster than ever before. COVID-19, a member of the coronavir...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

The spread of coronavirus has infected global share markets with the contagion of fear. The S&P/ASX 200 Index (INDEXASX: XJO) has fallen more than 10% in the last fortnight as investors flee to safe havens. This week, the Reserve Bank...

In February, mounting coronavirus-led uncertainty finally culminated in a late-month share price bloodbath. After a 3 per cent gain in January, the S&P/ASX Emerging Companies Index – which gauges the health of the microcap sector – had...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Michelle Miller, chief executive of...

As the coronavirus death toll rises to more than 1,000 and the World Health Organisation labels it a global health emergency, share markets are feeling the impact of the outbreak with Australian ASX-listed stocks not immune to the damage. C...

With the market returning to form and charging higher on Tuesday, it will come as no surprise to learn that a good number of shares pushed higher. Some that pushed so hard they ended up reaching 52-week highs or better are listed below. He...

Today’s session proved much kinder to the Aussie market, delivering strong gains across the board as China’s factories came back online. While the dollar remained fairly stagnant, sectors, futures and indices did a 180, rallying to rever...